source
- Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage studyPemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics, among oth…
- An eye drug biotech banks $118M and stocks its executive suiteClaris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.